BiotechTube

KHK7580

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperparathyroidism

Conditions

Hyperparathyroidism

Trial Timeline

Aug 1, 2013 → Mar 1, 2014

NCT ID
NCT01935856

About KHK7580

KHK7580 is a phase 1/2 stage product being developed by Kyowa Kirin for Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT01935856. Target conditions include Hyperparathyroidism.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (5)

NCT IDPhaseStatus
NCT03280264Phase 3Completed
NCT02549417Phase 3Completed
NCT02549404Phase 3Completed
NCT02143271Phase 1Completed
NCT01935856Phase 1/2Completed

Competing Products

20 competing products in Hyperparathyroidism

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
52
KHK7580 + KRN1493Kyowa KirinPhase 2/3
65
KHK7580Kyowa KirinPhase 1
33
KHK7580Kyowa KirinPhase 3
77
KHK7580Kyowa KirinPhase 3
77
Cinacalcet HClKyowa KirinApproved
85
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
77
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
52
Paricalcitol + CalcitriolAbbViePre-clinical
23
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
77
Paricalcitol + CalcifediolAbbVieApproved
85
Paricalcitol + Darbepoetin alfaAbbVieApproved
85
Alendronate 70mg weeklyMerckApproved
85
EtelcalcetideAmgenPhase 3
76
Cinacalcet + PlaceboAmgenPhase 2
51
Cinacalcet + PlaceboAmgenPhase 3
76
Etelcalcetide + PlaceboAmgenPhase 1
32
Sensipar (Cinacalcet HCl)AmgenPhase 2
51
AMG 073 + PlaceboAmgenPhase 3
76
cinacalcetAmgenPhase 3
76

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85